PDT Partners LLC Has $969,000 Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

PDT Partners LLC reduced its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 32,187 shares of the biopharmaceutical company's stock after selling 28,482 shares during the period. PDT Partners LLC's holdings in TG Therapeutics were worth $969,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in TGTX. Clearbridge Investments LLC bought a new position in shares of TG Therapeutics during the 4th quarter worth approximately $55,237,000. Principal Financial Group Inc. lifted its stake in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at approximately $14,508,000. Braun Stacey Associates Inc. acquired a new position in shares of TG Therapeutics in the fourth quarter valued at $13,328,000. Finally, Norges Bank acquired a new stake in TG Therapeutics during the fourth quarter worth approximately $12,085,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Trading Down 12.8 %

Shares of NASDAQ TGTX traded down $5.56 during midday trading on Monday, reaching $37.88. The stock had a trading volume of 10,992,985 shares, compared to its average volume of 3,020,295. The firm has a market cap of $6.01 billion, a price-to-earnings ratio of -378.77 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The company's 50 day moving average price is $38.56 and its 200 day moving average price is $33.31.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's quarterly revenue was up 90.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.07) EPS. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the topic of several research reports. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.